Patents by Inventor Joanna Grudzinska-Goebel
Joanna Grudzinska-Goebel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11529356Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 21, 2020Date of Patent: December 20, 2022Assignee: Bayer Pharma AktiengesellschaftInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Patent number: 11046783Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: GrantFiled: March 4, 2019Date of Patent: June 29, 2021Assignee: Bayer Pharma AktiengesellschaftInventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
-
Publication number: 20200383991Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 21, 2020Publication date: December 10, 2020Applicant: Bayer Pharma AktiengesellschaftInventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 10772893Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 8, 2018Date of Patent: September 15, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Publication number: 20190284300Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: ApplicationFiled: March 4, 2019Publication date: September 19, 2019Applicant: Bayer Pharma AktiengesellschaftInventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
-
Patent number: 10221247Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: GrantFiled: August 30, 2017Date of Patent: March 5, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
-
Publication number: 20180256591Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 8, 2018Publication date: September 13, 2018Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 10040866Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: GrantFiled: August 30, 2017Date of Patent: August 7, 2018Assignee: Bayer Pharma AktiengesellschaftInventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Y. Leung, Erik Tucker
-
Patent number: 9993484Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 3, 2015Date of Patent: June 12, 2018Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Lars Wortmann, Ulrich Lücking, Julien LeFranc, Hans Briem, Marcus Koppitz, Knut Eis, Franz Von Nussbaum, Benjamin Bader, Antje Margret Wengner, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Joanna Grudzinska-Goebel, Dieter Moosmayer, Uwe Eberspächer, Hans Schick
-
Publication number: 20180112009Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: ApplicationFiled: August 30, 2017Publication date: April 26, 2018Inventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
-
Publication number: 20180051093Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: ApplicationFiled: August 30, 2017Publication date: February 22, 2018Inventors: Andreas WILMEN, Julia STRAßBURGER, Frank DITTMER, Michael STRERATH, Anja BUCHMÜLLER, Joanna GRUDZINSKA-GOEBEL, Ricarda FINNERN, Martina SCHÄFER, Christoph GERDES, Hannah JÖRIßEN, Asako ITAKURA, Philberta Y. LEUNG, Erik TUCKER
-
Patent number: 9783614Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: GrantFiled: May 8, 2013Date of Patent: October 10, 2017Assignee: Bayer Pharma AktiengesellschaftInventors: Andreas Wilmen, Julia Straβburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jöriβen, Asako Itakura, Philberta Leung, Erik Tucker
-
Publication number: 20170216304Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 3, 2015Publication date: August 3, 2017Inventors: Lars WORTMANN, Ulrich LÜCKING, Julien LEFRANC, Hans BRIEM, Marcus KOPPITZ, Knut EIS, Franz VON NUSSBAUM, Benjamin BADER, Antje Margret WENGNER, Gerhard SIEMEISTER, Wilhelm BONE, Philip LIENAU, Joanna GRUDZINSKA-GOEBEL, Dieter MOOSMAYER, Uwe EBERSPÄCHER, Hans SCHICK
-
Patent number: 9549932Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 19, 2016Date of Patent: January 24, 2017Assignee: Bayer Pharma AktiengesellschaftInventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Franz Von Nussbaum, Benjamin Bader, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Dieter Moosmayer, Uwe Eberspächer, Hans Schick, Knut Eis, Marcus Koppitz, Antje Margret Wengner, Joanna Grudzinska-Goebel
-
Publication number: 20160287604Abstract: The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 19, 2016Publication date: October 6, 2016Inventors: Lars Wortmann, Ulrich Lücking, Julien Lefranc, Hans Briem, Franz Von Nussbaum, Benjamin Bader, Gerhard Siemeister, Wilhelm Bone, Philip Lienau, Dieter Moosmayer, Uwe Eberspächer, Hans Schick, Knut Eis, Marcus Koppitz, Antje Margret Wengner, Joanna Grudzinska-Goebel
-
Publication number: 20150099298Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.Type: ApplicationFiled: May 8, 2013Publication date: April 9, 2015Inventors: Andreas Wilmen, Julia Straßburger, Frank Dittmer, Michael Strerath, Anja Buchmüller, Joanna Grudzinska-Goebel, Ricarda Finnern, Martina Schäfer, Christoph Gerdes, Hannah Jörißen, Asako Itakura, Philberta Leung, Erik Tucker
-
Publication number: 20140050743Abstract: The present invention relates to the identification and use of antigen-binding regions, antibodies, antigen-binding antibody fragments and antibody mimetics, neutralizing the anti-coagulant effect of an anticoagulant in vitro and/or in vivo. Antibodies and functional fragments of the invention and antibody mimetics can be used to specifically reverse the pharmacological effect of an anticoagulant e.g. a FXa inhibitor for therapeutic (antidote) and/or diagnostic purposes. The invention also provides nucleic acid sequences encoding foregoing molecules, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: ApplicationFiled: January 17, 2012Publication date: February 20, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Frank Dittmer, Anja Buchmüller, Christoph Gerdes, Adrian Tersteegen, Mark Jean Gnoth, Lars Linden, Axel Harrenga, Joanna Grudzinska-Goebel, Mario Jeske, Martina Schäfer, Jörg Birkenfeld, Holger Paulsen, Ricarda Finnern, Anke Mayer-Bartschmid, Andrea Eicker, Simone Greven, Susanne Steinig
-
Patent number: RE47150Abstract: Isolated monoclonal antibodies that bind human tissue factor pathway inhibitor (TFPI) are provided. Isolated nucleic acid molecules encoding monoclonal antibodies that bind TFPI are also contemplated. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treating deficiencies or defects in coagulation by administration of the antibodies are also provided. Methods of producing the antibodies are also provided.Type: GrantFiled: July 12, 2016Date of Patent: December 4, 2018Assignee: Bayer HealthCare LLCInventors: Zhuozhi Wang, Junliang Pan, Joanna Grudzinska-Goebel, Christian Votsmeier, Jan Tebbe, Joerg Birkenfeld, Nina Wobst, Simone Brückner, Susanne Steinig, Peter Scholz